Eupraxia Pharmaceuticals (EPRX) AI Stock Analysis

• Market Cap: C$565.37M
• Dividend Yield: N/A
• Average Volume (3M): 53.43K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.96
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: 33
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.27
• Shares Outstanding: 50,648,330
• 10 Day Avg. Volume: 45,847
• 30 Day Avg. Volume: 53,430
• PEG Ratio: 0.13
• Price to Book (P/B): 4.58
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.08
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$20.84
• Price Target Upside: 88.77% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -0.83
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: C$12.50 ▲(13.22% Upside)
• Action: Reiterated Date: 02/04/26
• Date: Action: Reiterated 02/04/26

The score is held back primarily by weak financial performance (pre-revenue, ongoing losses and cash burn), partially offset by a conservatively levered balance sheet. Technicals are the main positive, showing a clear uptrend and constructive momentum, while valuation is constrained by negative earnings and no dividend data.

Positive Factors

Proprietary delivery platform

Eupraxia's DiffuSphere platform targets localized delivery for chronic conditions, a substantive technical moat. Durable advantage: improved local efficacy and lower systemic side effects can increase clinical success odds, enable niche positioning, and create licensing or partnership value over the medium term.

Conservative leverage

Extremely low debt relative to equity reduces refinancing and solvency risk, extending operational runway for a pre-revenue biotech. This structural strength supports sustained R&D activity and strategic optionality (partnering or disciplined financing) over the next several quarters.

Transparent cash usage

Free cash flow closely tracking net losses indicates cash burn reflects real operating costs, not hidden accruals. Improvement versus prior year suggests rising cash efficiency, which enhances predictability for financing needs and planning of clinical milestones over coming quarters.

Negative Factors

Pre-revenue status

No product revenue forces reliance on external capital to fund operations and trials. Persistent large net losses increase dilution risk and constrain long-term margin improvement until commercialization or licensing, making operational sustainability contingent on successful milestone events.

Negative profitability profile

Sustained negative gross profit and large operating losses show the business is still investing heavily with no revenue offset. This structural unprofitability means shareholder value depends on binary clinical/regulatory outcomes and eventual commercial execution, a long-duration risk.

Historic capital-structure volatility

Prior periods of higher leverage indicate management has used debt in the past, raising the possibility of refinancing pressure or covenant constraints if funding windows tighten. Historical volatility in capital structure adds execution and financing risk for a development-stage firm.

Eupraxia Pharmaceuticals Business Overview & Revenue Model

Company Description

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

How the Company Makes Money

Eupraxia Pharmaceuticals primarily generates revenue through the development and potential commercialization of its drug candidates. The company is focused on advancing its lead product candidates through clinical trials, seeking regulatory approval, and ultimately bringing these products to market. Revenue is expected to be derived from product sales, licensing agreements, and strategic partnerships. Eupraxia may engage in collaborations with larger pharmaceutical companies to co-develop or commercialize its products, thus gaining access to additional resources and market channels. However, as a clinical-stage company, Eupraxia's current revenue is likely limited and largely dependent on funding from investors, grants, or milestone payments from partnerships until its products receive regulatory approval and can be commercialized.

Eupraxia Pharmaceuticals Financial Statement Overview

Summary

Development-stage profile with no revenue and persistent, sizable net losses and cash burn (TTM net loss ~-$35M; TTM FCF ~-$25M). The main offset is a stronger, conservatively levered balance sheet in the latest periods (very low debt vs equity), reducing near-term solvency risk.

Income Statement

The company remains pre-revenue across the annual periods and in TTM (Trailing-Twelve-Months), with gross profit negative each year and sizable operating losses. Net losses are consistently large (roughly $23M–$37M annually; TTM net loss ~$35M), indicating a business still in heavy investment mode with no visible revenue ramp in the provided data. A modest positive is that losses are not accelerating meaningfully versus 2023–2024, but the absence of revenue and persistent losses keep income-statement quality weak.

Balance Sheet

Leverage looks very conservative in the latest periods, with extremely low debt relative to equity in 2024 and TTM (Trailing-Twelve-Months). Equity and assets are also substantially higher in TTM versus 2024, suggesting improved capitalization. The key weakness is profitability: returns on equity are deeply negative in all recent periods due to ongoing losses, and the capital structure was meaningfully riskier in 2023 (high debt relative to equity), showing historical volatility.

Cash Flow

Cash burn remains heavy: operating cash flow is negative in every period, including TTM (Trailing-Twelve-Months) at about -$24.8M, and free cash flow is similarly negative (TTM about -$25.2M). Cash outflow did improve versus 2024 (less negative operating and free cash flow), but the TTM free cash flow decline versus the prior period (negative growth) highlights continued funding needs. A relative positive is that free cash flow broadly tracks net loss (free cash flow to net income near 1x), indicating losses are largely reflected in cash usage rather than being masked by accounting effects.

Breakdown	TTM	Dec 2024	Mar 2024	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-306.40K	-235.25K	-209.91K	-193.27K	-111.53K	-116.81K
EBITDA	-31.61M	-33.72M	-37.40M	-22.14M	-21.96M	-2.01M
Net Income	-35.06M	-34.94M	-37.39M	-23.26M	-22.99M	-4.00M
Balance Sheet
Total Assets	128.50M	50.24M	26.72M	25.88M	31.22M	1.45M
Cash, Cash Equivalents and Short-Term Investments	123.78M	33.10M	19.34M	24.74M	29.90M	150.13K
Total Debt	237.38K	103.31K	10.45M	10.55M	9.49M	12.77M
Total Liabilities	5.43M	4.46M	25.55M	14.51M	11.67M	23.12M
Stockholders Equity	125.27M	33.40M	2.22M	12.86M	20.39M	-21.21M
Cash Flow
Free Cash Flow	-25.24M	-30.10M	-28.02M	-19.08M	-15.07M	-403.93K
Operating Cash Flow	-24.80M	-29.99M	-27.92M	-18.78M	-14.64M	-403.93K
Investing Cash Flow	-439.40K	-75.16K	-99.03K	8.70M	-14.45M	24.62K
Financing Cash Flow	106.30M	45.78M	27.84M	13.52M	49.92M	-626.64K

Eupraxia Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 11.04
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EPRX, the sentiment is Neutral. The current price of 11.04 is below the 20-day moving average (MA) of 11.40, below the 50-day MA of 11.24, and above the 200-day MA of 8.39, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 46.30 is Neutral, neither overbought nor oversold. The STOCH value of 60.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:EPRX.

Eupraxia Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EPRX	57 Neutral	C$565.37M	-7.83	-59.46%	―	―	―
NGEN	53 Neutral	C$430.60M	-14.39	-790.82%	―	―	2.22%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ENBI	47 Neutral	C$1.39M	-6.62	-107.76%	―	―	34.22%
DRUG	44 Neutral	C$1.06B	-28.32	-30.79%	―	―	-43.64%

Eupraxia Pharmaceuticals Corporate Events

Eupraxia Posts Strong Mid-Stage Data for Once-Yearly EoE Therapy EP-104GI

Eupraxia Pharmaceuticals reported encouraging interim results from the Phase 1b/2a portion of its RESOLVE trial of EP-104GI in eosinophilic esophagitis, showing near-complete normalization of esophageal tissue health at the highest dose by week 12 and sustained improvements at lower doses out to week 36. A majority of patients who had at least 60% of their esophagus treated achieved and maintained clinical remission for up to 52 weeks after a single administration, with more than 200 patient-months of follow-up showing no serious adverse events or oral candidiasis, bolstering EP-104GI’s profile as a potentially once-yearly treatment and supporting ongoing recruitment in the randomized Phase 2b trial, with top-line data expected in 2026.

The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$16.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see the TSE:EPRX Stock Forecast page.